Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: B.D. who wrote (21694)	6/2/1998 12:57:00 PM
From: Webhead	Read Replies (3) \| Respond to of 32384

News! Well, RB I guess Bears know about going out on limbs! Volume going berzerk 581K 14 X 14 1/16 GAITHERSBURG, Md.,, June 2 (Reuters) - A Food and Drug Administration advisory panel recommended approval of Seragen Inc.'s new drug, Ontak, to treat a rare cancer called cutaneous T-cell lymphoma. The panel did not vote on U.S. Food and Drug Administration (FDA) approval, but said that the drug was safe and effective. Ontak was developed by Seragen and Eli Lilly and Co. . Ligand Pharmaceuticals will assume the rights to Ontak if a merger with Seragen is approved by the Securities and Exchange Commission. If the FDA follows the panel's advice, which it usually does, Ontak could be approved in six months.

To: B.D. who wrote (21694)	6/9/1998 7:34:00 AM
From: tonyt	Respond to of 32384

>I appreciate your tireless efforts to inform LGND investors on the scientific foundation >of the company, but I humbly suggest you refrain from hyping your website >in SI like this. 100 accesses per hour of your web page is not impressive. >1 million per hour might be. Looks like your 'humble request' was denied ;-) --Tony

To: B.D. who wrote (21694)	6/9/1998 9:06:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

BD, I agree that a million hits per hour at the web site would be impressive, but I think that the 100 hits per hour is also significant. The hits are not a random selection of net surfers. Most of those interested are from the industry. The web site was designed to provide quick access to material associated with LGND. Addressing the concern about dilution is a good example of the utility of the site. LGND is a very complex company. Most investors (including institutions) really don't understand biotechs very well. The know even less about the underlying science. The web site allows quick access to this info. Before the site existed, I would dig out old articles to support an explanation or provide background. It's much easier to link the site, so readers (and there are far more lurkers than posters) can easily get to the information themselves. Thus if they want to see LGND's pipeline, they just click on home.att.net If they want to see some of LGND's clinical trials they click on home.att.net If they want background on the STAt technology or the molecular mimics of G-CSF they click on home.att.net It's easy for some to have concern about LGND's outstanding shares. However, its also easy to overlook LGND's pipeline, clinical trials, patents, and core technologies. the web site allows this information to be easily accessed. LGND is a rather unique Biotech, although I think that other Biotechs would benefit from such information, especially if they are complex like LGND is. Lurkers continue to visit and revisit the site at frequencies that I consider significant. Everyone has their own opinions (and humble requests). As far as supporting documents on the web are concerned, I have tried using links in the past. Frequently these links only last a day or two and therefore have limited utility, especially for the web site. I have stopped uploading such documents here. Of course others continue to upload such information here and throughout SI. On this board you can even find such documents on such relevant subjects such as DELL.